Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.
Back to dashboard
Company Information
About this company
Key people
Steven M. Paul
Director and Chairman of the Board
Sandra E. Peterson
Independent Director
Jason Pitts
Independent Director
Daphne Zohar
President, Chief Executive Officer, Director
Lauren A. White
Chief Financial Officer
Michael C. Chen
Chief Scientific Officer
Lana Gladstein
General Counsel
Antony Loebel
Chief Medical Officer, President - Clinical Development
Sharon Mates
Director
James I. Healy
Independent Director
Robert J. Hombach
Independent Director
Click to see more
Key facts
- Shares in issue53.53m
- EPICSPTX
- ISINUS81221K1088
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$954.45m
- Employees58
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.